Seres Therapeutics Inc
MCRB
Company Profile
Business description
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Contact
101 Cambridgepark Drive
CambridgeMA02140
USAT: +1 617 945-9626
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
66
Stocks News & Analysis
stocks
Big 4 earnings: Morningstar analysts form view on impact of slowing housing market
Big 4 bank maintains Fair Value, Short-term earnings not material enough to shift valuation for key player
stocks
ASX healthcare share remains cheap despite mixed earnings result
Shares in Aussie listed healthcare name undervalued post earnings.
stocks
Wide moat ASX share beats earnings guidance
Wide moat share continues to grow despite a challenging residential construction market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,404.70 | 0.80 | -0.01% |
| CAC 40 | 8,709.51 | 5.43 | -0.06% |
| DAX 40 | 26,508.89 | 117.47 | 0.45% |
| Dow JONES (US) | 53,791.85 | 184.13 | -0.34% |
| FTSE 100 | 10,848.80 | 4.61 | 0.04% |
| HKSE | 25,440.17 | 212.65 | -0.83% |
| NASDAQ | 26,445.45 | 159.91 | -0.60% |
| Nikkei 225 | 67,524.06 | 553.84 | 0.83% |
| NZX 50 Index | 13,737.66 | 123.00 | -0.89% |
| S&P 500 | 7,728.20 | 24.91 | -0.32% |
| S&P/ASX 200 | 9,209.40 | 2.20 | -0.02% |
| SSE Composite Index | 3,946.68 | 12.58 | 0.32% |